NewYue Biotechnology has secured strategic A+ round funding led by XtalPi Technology to integrate DNA-Encoded Compound Library technology with AI, aiming to accelerate innovative drug development efforts.
Target Information
NewYue Biotechnology, established in April 2021 and incubated by the Guangdong Small Molecule New Drug Innovation Center, is a clinical-stage innovative drug development company based in Shenzhen, China. The company specializes in DNA-Encoded Compound Library (DEL) technology, boasting a repository of over 100 billion tangible molecular compounds. NewYue's proprietary DEL live-cell screening technology effectively identifies challenging targets for purification, significantly broadening the target range and hit rate for new drug screening.
With a mission to empower new drug development through unique technology, NewYue aims to become a leading biopharmaceutical firm known for its distinctive capabilities and its commitment to creating affordable, effective medications for the general public.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The integration of biotechnology and information technology has become a significant trend in the pharmaceutical industry, particularly with the rising adoption of Artificial Intelligence (AI) in drug development. This transformation is reshaping traditional
Similar Deals
Apricot Capital → Vibrant Therapeutics (Guangzhou) Co., Ltd.
2025
XtalPi Holdings Limited
invested in
Shenzhen Xinyue Biotechnology Co., Ltd.
in 2025
in a Series A deal